Cargando…
von Willebrand factor, ADAMTS-13, and thrombospondin 1 in relation to clinical outcomes in elderly patients with a recent myocardial infarction
BACKGROUND: von Willebrand factor (VWF) multimers are cleaved by A disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13 (ADAMTS-13) into less active fragments. Thrombospondin 1 (TSP-1) competes with VWF’s cleavage site, protecting it from degradation. Low ADAMTS-13 and high...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225923/ https://www.ncbi.nlm.nih.gov/pubmed/37255854 http://dx.doi.org/10.1016/j.rpth.2023.100164 |
_version_ | 1785050477535166464 |
---|---|
author | Warlo, Ellen M.K. Kalstad, Are A. Myhre, Peder L. Solheim, Svein Arnesen, Harald Tveit, Arnljot Holme, Pål Andre Seljeflot, Ingebjørg Bratseth, Vibeke |
author_facet | Warlo, Ellen M.K. Kalstad, Are A. Myhre, Peder L. Solheim, Svein Arnesen, Harald Tveit, Arnljot Holme, Pål Andre Seljeflot, Ingebjørg Bratseth, Vibeke |
author_sort | Warlo, Ellen M.K. |
collection | PubMed |
description | BACKGROUND: von Willebrand factor (VWF) multimers are cleaved by A disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13 (ADAMTS-13) into less active fragments. Thrombospondin 1 (TSP-1) competes with VWF’s cleavage site, protecting it from degradation. Low ADAMTS-13 and high VWF have been associated with cardiovascular disease and atrial fibrillation (AF). OBJECTIVES: We aimed to investigate whether VWF, ADAMTS-13, and TSP-1 are associated with clinical outcome. METHODS: Elderly patients with a recent myocardial infarction (MI) (n = 1027) were followed for 2 years. Blood was collected 2 to 8 weeks after the MI for ADAMTS-13, VWF, and TSP-1 measures. The primary endpoints (major adverse cardiovascular events; n = 210) included the first event of MI, stroke, heart failure hospitalization, coronary revascularization, and all-cause death. Total mortality was also registered (n = 56). The secondary endpoint was new-onset AF (n = 43). RESULTS: Concentrations of VWF, ADAMTS-13, and TSP-1 did not intercorrelate. The risk of major adverse cardiovascular events was altered in patients with VWF ≥ median (hazard ratio [HR], 1.4; 95% CI, 1.0-1.8; P = .03) and ADAMTS-13 ≥ median (HR, 0.7; 95% CI, 0.5-0.9; P = .02); however, it was not significant in adjusted models. VWF and ADAMTS-13 were significantly associated with total mortality, with a HR of 2.7 (95% CI, 1.6-4.6; P < .001) for VWF (Q4 vs. Q1-Q3) and HR of 0.3 (95% CI, 0.2-0.5; P < .001) for ADAMTS-13 (Q2-4 vs. Q1). The associations persisted in multivariable analysis, but the significance disappeared for VWF after correcting for high-sensitivity C-reactive protein. The risk of new-onset AF was lower in patients with VWF ≥ median (HR, 0.5; 95% CI, 0.3-1.0; P = .04]), and this was still significant after adjustments. CONCLUSION: Although low ADAMTS-13 predicted death, the cardiovascular risk associated with VWF and ADAMTS-13 was weaker than previously reported. Low VWF is associated with new-onset AF and needs further research. |
format | Online Article Text |
id | pubmed-10225923 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-102259232023-05-30 von Willebrand factor, ADAMTS-13, and thrombospondin 1 in relation to clinical outcomes in elderly patients with a recent myocardial infarction Warlo, Ellen M.K. Kalstad, Are A. Myhre, Peder L. Solheim, Svein Arnesen, Harald Tveit, Arnljot Holme, Pål Andre Seljeflot, Ingebjørg Bratseth, Vibeke Res Pract Thromb Haemost Original Article BACKGROUND: von Willebrand factor (VWF) multimers are cleaved by A disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13 (ADAMTS-13) into less active fragments. Thrombospondin 1 (TSP-1) competes with VWF’s cleavage site, protecting it from degradation. Low ADAMTS-13 and high VWF have been associated with cardiovascular disease and atrial fibrillation (AF). OBJECTIVES: We aimed to investigate whether VWF, ADAMTS-13, and TSP-1 are associated with clinical outcome. METHODS: Elderly patients with a recent myocardial infarction (MI) (n = 1027) were followed for 2 years. Blood was collected 2 to 8 weeks after the MI for ADAMTS-13, VWF, and TSP-1 measures. The primary endpoints (major adverse cardiovascular events; n = 210) included the first event of MI, stroke, heart failure hospitalization, coronary revascularization, and all-cause death. Total mortality was also registered (n = 56). The secondary endpoint was new-onset AF (n = 43). RESULTS: Concentrations of VWF, ADAMTS-13, and TSP-1 did not intercorrelate. The risk of major adverse cardiovascular events was altered in patients with VWF ≥ median (hazard ratio [HR], 1.4; 95% CI, 1.0-1.8; P = .03) and ADAMTS-13 ≥ median (HR, 0.7; 95% CI, 0.5-0.9; P = .02); however, it was not significant in adjusted models. VWF and ADAMTS-13 were significantly associated with total mortality, with a HR of 2.7 (95% CI, 1.6-4.6; P < .001) for VWF (Q4 vs. Q1-Q3) and HR of 0.3 (95% CI, 0.2-0.5; P < .001) for ADAMTS-13 (Q2-4 vs. Q1). The associations persisted in multivariable analysis, but the significance disappeared for VWF after correcting for high-sensitivity C-reactive protein. The risk of new-onset AF was lower in patients with VWF ≥ median (HR, 0.5; 95% CI, 0.3-1.0; P = .04]), and this was still significant after adjustments. CONCLUSION: Although low ADAMTS-13 predicted death, the cardiovascular risk associated with VWF and ADAMTS-13 was weaker than previously reported. Low VWF is associated with new-onset AF and needs further research. Elsevier 2023-04-23 /pmc/articles/PMC10225923/ /pubmed/37255854 http://dx.doi.org/10.1016/j.rpth.2023.100164 Text en © 2023 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Original Article Warlo, Ellen M.K. Kalstad, Are A. Myhre, Peder L. Solheim, Svein Arnesen, Harald Tveit, Arnljot Holme, Pål Andre Seljeflot, Ingebjørg Bratseth, Vibeke von Willebrand factor, ADAMTS-13, and thrombospondin 1 in relation to clinical outcomes in elderly patients with a recent myocardial infarction |
title | von Willebrand factor, ADAMTS-13, and thrombospondin 1 in relation to clinical outcomes in elderly patients with a recent myocardial infarction |
title_full | von Willebrand factor, ADAMTS-13, and thrombospondin 1 in relation to clinical outcomes in elderly patients with a recent myocardial infarction |
title_fullStr | von Willebrand factor, ADAMTS-13, and thrombospondin 1 in relation to clinical outcomes in elderly patients with a recent myocardial infarction |
title_full_unstemmed | von Willebrand factor, ADAMTS-13, and thrombospondin 1 in relation to clinical outcomes in elderly patients with a recent myocardial infarction |
title_short | von Willebrand factor, ADAMTS-13, and thrombospondin 1 in relation to clinical outcomes in elderly patients with a recent myocardial infarction |
title_sort | von willebrand factor, adamts-13, and thrombospondin 1 in relation to clinical outcomes in elderly patients with a recent myocardial infarction |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225923/ https://www.ncbi.nlm.nih.gov/pubmed/37255854 http://dx.doi.org/10.1016/j.rpth.2023.100164 |
work_keys_str_mv | AT warloellenmk vonwillebrandfactoradamts13andthrombospondin1inrelationtoclinicaloutcomesinelderlypatientswitharecentmyocardialinfarction AT kalstadarea vonwillebrandfactoradamts13andthrombospondin1inrelationtoclinicaloutcomesinelderlypatientswitharecentmyocardialinfarction AT myhrepederl vonwillebrandfactoradamts13andthrombospondin1inrelationtoclinicaloutcomesinelderlypatientswitharecentmyocardialinfarction AT solheimsvein vonwillebrandfactoradamts13andthrombospondin1inrelationtoclinicaloutcomesinelderlypatientswitharecentmyocardialinfarction AT arnesenharald vonwillebrandfactoradamts13andthrombospondin1inrelationtoclinicaloutcomesinelderlypatientswitharecentmyocardialinfarction AT tveitarnljot vonwillebrandfactoradamts13andthrombospondin1inrelationtoclinicaloutcomesinelderlypatientswitharecentmyocardialinfarction AT holmepalandre vonwillebrandfactoradamts13andthrombospondin1inrelationtoclinicaloutcomesinelderlypatientswitharecentmyocardialinfarction AT seljeflotingebjørg vonwillebrandfactoradamts13andthrombospondin1inrelationtoclinicaloutcomesinelderlypatientswitharecentmyocardialinfarction AT bratsethvibeke vonwillebrandfactoradamts13andthrombospondin1inrelationtoclinicaloutcomesinelderlypatientswitharecentmyocardialinfarction |